Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase Ib Multi-Cohort Study of MK-3475 in Subjects With Advanced Solid Tumors
Brief Summary: This study is being done to investigate the safety, tolerability and anti-tumor activity of pembrolizumab (MK-3475) in participants with advanced triple negative breast cancer (TNBC) (Cohort A), advanced head and neck cancer (Cohorts B and B2), advanced urothelial cancer (Cohort C), or advanced gastric cancer (Cohort D). Additionally, for Cohort D, data is presented for Asian Pacific (AP) participants. Only participants with programmed cell death-ligand 1 (PD-L1) expressing tumors were enrolled in Cohorts A, B, C and D. Participants in Cohort B2 were enrolled irrespective of PD-L1 status.

The primary study hypothesis is that pembrolizumab is safe and well-tolerated.


Options:
A: Arm Label: Cohort A: Triple Negative Breast Cancer; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Cohort B: Head & Neck Cancer; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Cohort C: Urothelial Cancer; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Cohort D: Gastric Cancer; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Cohort B2: Head & Neck Cancer Expansion; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): Cohort A: Triple Negative Breast Cancer, Cohort B2: Head & Neck Cancer Expansion, Cohort B: Head & Neck Cancer, Cohort C: Urothelial Cancer, Cohort D: Gastric Cancer
B: Arm Label: Escalation Cohort (MEDI4736 0.1 mg/kg Q2W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Escalation Cohort (MEDI4736 0.3 mg/kg Q2W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Escalation Cohort (MEDI4736 1 mg/kg Q2W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Escalation Cohort (MEDI4736 3 mg/kg Q2W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Escalation Cohort (MEDI4736 10 mg/kg Q2W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Escalation Cohort (MEDI4736 15 mg/kg Q3W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Exploration Durvalumab 20 mg/kg (Q4W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Expansion SCCHN Cohort (MEDI4736 10 mg/kg Q2W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Expansion Non-SCCHN Cohort HPV positive (MEDI4736 10 mg/kg Q2W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Expansion NSCLC Cohort (MEDI4736 10 mg/kg Q2W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Expansion HCC Total Cohort (MEDI4736 10 mg/kg Q2W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Expansion ACM Cohort (MEDI4736 10 mg/kg Q2W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Expansion UM Cohort (MEDI4736 10 mg/kg Q2W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Expansion GEC Cohort (MEDI4736 10 mg/kg Q2W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Expansion TNBC Cohort (MEDI4736 10 mg/kg Q2W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Expansion PAC Cohort (MEDI4736 10 mg/kg Q2W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Expansion UC Cohort (MEDI4736 10 mg/kg Q2W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Expansion GBM Cohort (MEDI4736 10 mg/kg Q2W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Expansion OC Cohort (MEDI4736 10 mg/kg Q2W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Expansion STS Cohort (MEDI4736 10 mg/kg Q2W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Expansion SCLC Cohort (MEDI4736 10 mg/kg Q2W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Expansion MSI-high Cancer Cohort (MEDI4736 10 mg/kg Q2W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Expansion NPC Cohort (MEDI4736 10 mg/kg Q2W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Intervention Type: DRUG; Name: MEDI4736; Assigned to Arm(s): Escalation Cohort (MEDI4736 0.1 mg/kg Q2W), Escalation Cohort (MEDI4736 0.3 mg/kg Q2W), Escalation Cohort (MEDI4736 1 mg/kg Q2W), Escalation Cohort (MEDI4736 10 mg/kg Q2W), Escalation Cohort (MEDI4736 15 mg/kg Q3W), Escalation Cohort (MEDI4736 3 mg/kg Q2W), Expansion ACM Cohort (MEDI4736 10 mg/kg Q2W), Expansion GBM Cohort (MEDI4736 10 mg/kg Q2W), Expansion GEC Cohort (MEDI4736 10 mg/kg Q2W), Expansion HCC Total Cohort (MEDI4736 10 mg/kg Q2W), Expansion MSI-high Cancer Cohort (MEDI4736 10 mg/kg Q2W), Expansion NPC Cohort (MEDI4736 10 mg/kg Q2W), Expansion NSCLC Cohort (MEDI4736 10 mg/kg Q2W), Expansion Non-SCCHN Cohort HPV positive (MEDI4736 10 mg/kg Q2W), Expansion OC Cohort (MEDI4736 10 mg/kg Q2W), Expansion PAC Cohort (MEDI4736 10 mg/kg Q2W), Expansion SCCHN Cohort (MEDI4736 10 mg/kg Q2W), Expansion SCLC Cohort (MEDI4736 10 mg/kg Q2W), Expansion STS Cohort (MEDI4736 10 mg/kg Q2W), Expansion TNBC Cohort (MEDI4736 10 mg/kg Q2W), Expansion UC Cohort (MEDI4736 10 mg/kg Q2W), Expansion UM Cohort (MEDI4736 10 mg/kg Q2W), Exploration Durvalumab 20 mg/kg (Q4W)
C: Arm Label: Cohort 2: Participants With Second-line or Beyond Treatments; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab | Intervention Type: DRUG; Name: Atezolizumab; Assigned to Arm(s): Cohort 2: Participants With Second-line or Beyond Treatments
D: Arm Label: Atezolizumab+Gemcitabine+Carboplatin/Cisplatin; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab, Drug: Carboplatin, Drug: Gemcitabine, Drug: Cisplatin | Arm Label: Placebo+Gemcitabine+Carboplatin/Cisplatin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Gemcitabine, Other: Placebo, Drug: Cisplatin | Arm Label: Atezolizumab Monotherapy; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab | Intervention Type: DRUG; Name: Atezolizumab; Assigned to Arm(s): Atezolizumab Monotherapy, Atezolizumab+Gemcitabine+Carboplatin/Cisplatin | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Atezolizumab+Gemcitabine+Carboplatin/Cisplatin, Placebo+Gemcitabine+Carboplatin/Cisplatin | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Atezolizumab+Gemcitabine+Carboplatin/Cisplatin, Placebo+Gemcitabine+Carboplatin/Cisplatin | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo+Gemcitabine+Carboplatin/Cisplatin | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Atezolizumab+Gemcitabine+Carboplatin/Cisplatin, Placebo+Gemcitabine+Carboplatin/Cisplatin

Answer: A